Therapeutic Response

t(15;17) status confers therapeutic sensitivity to Arsenic trioxide in patients with Acute Promyelocytic Leukemia.

Statements

Source and description
Trisenox (arsenic trioxide) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
Trisenox (arsenic trioxide) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to arsenic trioxide for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.